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Abstract
Objective—To estimate the association between duration of combination antiretroviral therapy 
(cART) during pregnancy and low infant birthweight (LBW), among women ≥37 weeks gestation.
Design—We conducted a retrospective cohort study of HIV-infected women who met eligibility 
criteria based on CD4 count ≤350 but had not started cART at entry into antenatal care (ANC). 
Our cohort was restricted to births that occurred ≥37 weeks gestation.
Methods—We used Poisson models with robust variance estimators to estimate risk ratios (RR) 
and 95% confidence intervals (CI).
Results—Of 50,765 HIV-infected women with antenatal visits between January 2009 and 
September 2013, 4,474 women met the inclusion criteria. LBW occurred in 302 pregnancies (7%). 
Nearly two-thirds of women (62%) eligible to initiate cART never started treatment. Overall, 14% 
were on cART for ≤8 weeks, 22% for 9-20 weeks, and 2% for 21-36 weeks. There was no 
evidence of an increased risk of LBW for women receiving cART for ≤8 weeks (RR 1.22, 95% 
CI: 0.77, 1.91), 9-20 weeks (RR 1.23, 95% CI: 0.82, 1.83), or 21-36 weeks (RR 0.87, 95% CI: 
0.22, 3.46), compared to women who never initiated treatment. These findings were consistent 
across several sensitivity analyses.
Conclusions—Longer duration of cART was not associated with poor fetal growth among term 
pregnancies in our cohort. However, the relationship between cART and adverse pregnancy 
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outcomes remains complicated. Continued work is required to investigate causality. An 
understanding cART's impact on adverse pregnancy outcomes is essential as cART becomes the 
cornerstone of PMTCT programs globally.
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Introduction
In 2013, the World Health Organization (WHO) recommended lifetime combination 
antiretroviral therapy (cART) for all HIV-infected pregnant women in countries with a 
generalized HIV epidemic. Known as “Option B+,” this policy is currently being scaled up 
in several sub-Saharan African (SSA) countries, including Zambia.(1) Option B+ is 
expected to streamline treatment initiation for HIV-infected pregnant women by removing 
the need for CD4 count screening and simplifying treatment recommendations.(2) Improved 
access to treatment over time – and the resulting increase in women starting pregnancy 
already on cART – is expected to play a critical role in virtually eliminating new pediatric 
HIV infections and improving maternal health.(3)
However, cART use during pregnancy could negatively affect fetal growth. Adverse 
associations between cART during pregnancy and birthweight were first reported among 
HIV-infected pregnant women in Europe.(4, 5) These findings were not confirmed by 
studies in North and Latin America, where no adverse associations between cART and low 
birthweight (LBW; <2500 g) were observed.(6-9) cART with a protease inhibitor (PI) was 
associated with an increased odds of very low birthweight (VLBW; <1500 g) in a combined 
cohort study of 7 US sites, but the precision was poor, as very few outcomes were observed 
(n=16).(10) The relationship between cART and LBW among women in SSA is also 
unclear. cART has been associated with LBW among women in Cote d'Ivoire and small for 
gestational age among women Botswana.(11, 12) As cART access expands throughout SSA, 
the impact of longer durations of cART during pregnancy on LBW must be understood.
cART use during pregnancy could affect LBW through two different pathways: shortening 
gestation length (leading to preterm birth (PTB)) or restricting fetal growth. Duration of 
cART during pregnancy is directly related length of gestation, making it difficult to 
meaningfully assess the association between duration of treatment and PTB. We, therefore, 
limited our analysis cohort to those infants delivered at term. This approach allowed us to 
focus on the potential relationship between duration of cART and LBW among term infants, 
a proxy for intrauterine growth restriction (IUGR), in a population of HIV-infected women 
eligible to initiate cART for maternal health in Zambia.
Materials and Methods
Study Design and Setting
We conducted a retrospective cohort analysis of HIV-infected pregnant women attending 
public antenatal healthcare facilities in Lusaka, Zambia. Lusaka is an urban setting where 
Bengtson et al. Page 2
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 April 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
antenatal care (ANC) coverage has been consistently reported at >95%.(13) Over the study 
period, HIV testing and CD4 screening were conducted within antenatal clinics. Among 
women attending ANC, HIV testing is near universal and CD4 count screening coverage is 
approximately 80%.(14) Pregnant women who meet local eligibility criteria for cART 
receive services either in integrated ART-ANC clinics or stand-alone HIV treatment 
departments, typically co-located at the same primary healthcare facility. Comprehensive 
medical information, including HIV treatment information, has been captured by the Zambia 
Electronic Perinatal Record System (ZEPRS) since 2007 in all 24 public antenatal clinics in 
Lusaka.(14) Ethical approval was obtained from the University of Zambia Biomedical 
Research Ethics Committee (Lusaka, Zambia) and the University of North Carolina, Chapel 
Hill (Chapel Hill, NC) and informed consent was not obtained for the analysis of routinely 
collected clinical data.
Study Population
Women were included in the present analysis if they entered ANC after January 1, 2009 and 
delivered before September 1, 2013, were HIV-infected, had a CD4 count of ≤350 cells/uL 
(the threshold for ART eligibility during the study period), were not on cART at the time of 
presentation and delivered a singleton pregnancy at a public healthcare facility at ≥37 weeks 
gestation.(15, 16) Women who conceived while on cART were excluded since women who 
initiate cART and survive long enough to get pregnant may not be comparable to women 
initiating cART during pregnancy.(17) Therefore our interest was in a population of women 
newly initiating cART. Duration of cART is directly related to length of gestation; with each 
week that a woman remains pregnant and on cART, the probability of having a preterm birth 
diminishes. This could result in a spurious association between duration of treatment and 
preterm birth, where women on cART longer appear less likely to have a preterm birth. For 
this reason, we limited our analysis cohort to those infants delivered at term and focused on 
an outcome of LBW. In resource-limited settings such as Zambia, where ultrasound is not 
routinely available, LBW among infants delivered at term can be considered a proxy for 
IUGR.(18) We assessed LBW among term infants, rather than small for gestational age, as 
an outcome due to concerns about measurement error in gestational age for deliveries born 
prior to term.(19) Women with the following chronic conditions: heart disease, 
hypertension, and Type 2 diabetes have poorer pregnancy outcomes (20, 21) and may be 
more likely to seek ANC earlier due to their preexisting conditions. To minimize 
confounding, this group was also excluded.
Definitions
The exposure of interest was duration of cART before delivery, measured in completed 
weeks (e.g. 12 weeks and 4 days was considered 12 completed weeks) and categorized as 
never initiated (referent), ≤8 weeks, 9-20 weeks, and 21-36 weeks. Category cut-points were 
based on the functional form of the relationship between the exposure and outcome, as well 
as clinical considerations to approximately correspond with cART initiation in early, mid 
and late pregnancy. We also considered duration of cART before delivery as a continuous 
measure of weeks on cART. The primary outcome was a binary measure of LBW, defined 
as <2,500 grams.(22) Mean birthweight as a continuous measure was used as a secondary 
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outcome. Birthweight is measured in ZEPRS in kilograms (rounded to the nearest 
hundredth) and was converted to grams for this analysis.
Confounding variables were identified using directed acyclic graphs(23, 24) and included 
age, baseline body mass index (BMI), baseline CD4 count, baseline hemoglobin, education, 
parity, previous PTB (<37 weeks gestation), number of ANC visits and gestational age at 
birth. Number of ANC visits and education were used as proxies for health seeking 
behavior.(25-27) The functional form of the relationship between continuous confounders 
and outcome was assessed and confounders were modeled either as linear terms (age, CD4 
count and gestational age at birth) or using restricted quadratic splines (BMI and 
hemoglobin).(28) All potential confounders were included in multivariable models, unless 
otherwise noted. Information on viral load, WHO clinical stage, antiretroviral adherence and 
drug regimen was not available in our electronic medical record. However, recommended 
first line treatment in Zambia is a non-nucleoside reverse transcriptase inhibitor (NNRTI)-
based regimen.(29-31)
Gestational age was measured in completed weeks and calculated following standard 
clinical guidelines by last menstrual period (LMP) for pregnancies <20 weeks at time of 
enrollment into ANC. For those ≥20 weeks at enrollment, both LMP and symphysis-fundal 
height were used. If these two methods yielded gestational ages within 3 weeks of each 
other, the date based on the LMP was used. If not, the fundal height–derived gestational age 
was used. LMP was available for all women. Gestational age dating based on LMP is known 
to contain error.(32, 33) To assess the validity of gestational age dating in our data, we 
compared mean birthweight for each week of gestational age at birth to a reference growth 
curve adjusted to a Zambian population.(34) Comparisons with a reference growth curve 
values suggested substantial measurement error in gestational dating for women delivering 
before 35 weeks. For women delivering at ≥35 weeks gestation, mean birthweights were 
comparable to reference curve values, indicating relatively unbiased gestational age dating 
(Web Appendix Figure 1).
Statistical analyses
In the primary analysis, we used multivariable Poisson models with robust variance 
estimators to estimate risk ratios (RRs) and 95% confidence intervals (CIs)(35) for the 
association between categories of duration of cART before delivery and LBW. In secondary 
analysis, we used multivariable linear regression to estimate the association between 
duration of cART before delivery and birthweight, treating duration of cART first as a 
continuous measure (weeks on cART) and then as a categorical measure.
We additionally performed several sensitivity analyses. First, to minimize the impact of 
length of time in care, we compared women in each category of cART duration to a referent 
of women who never initiated cART, but were enrolled in ANC for the same duration of 
time. Second, we stratified the association between cART duration and LBW by baseline 
CD4 count to see if women with greater immunosuppression were at a higher risk of LBW. 
Third, we assessed women's duration of cART at 37 weeks gestation (instead of at delivery) 
so that treatment duration was assessed before women reached term. Finally, we included all 
Bengtson et al. Page 4
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 April 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
women who initiated cART with a CD4 count>350 (n=214) to make results as generalizable 
as possible to a setting where Option B+ has been implemented.
As with many sources of routinely collected clinical information, missing data was a 
concern. To address possible bias from missing data, in a sensitivity analysis we assessed 
predictors of missing 1) CD4 counts among all HIV-infected pregnant women, 2) cART 
initiation dates 3) confounders and 4) missing data 1-3 combined (all missing data imputed) 
and performed multiple imputation (n=50 imputations) for the missing data. All statistical 
analyses were performed using SAS version 9.2 (SAS Institute Inc. Cary, NC).
Results
Among 50,765 HIV-infected pregnant women enrolled in ANC, 4,474 women met inclusion 
criteria for our study cohort (Figure 1). LBW occurred in 302 of pregnancies (7%). 
Nulliparity was more common among women who had a LBW infant, than among women 
with normal birthweight infants (29% versus 18%, p-value 0.08). Median baseline BMI and 
CD4 count values were similar between those delivering LBW and normal birthweight 
infants. Only 10% of women attended ≥4 ANC visits, as recommended by the WHO (Table 
1).(36)
Of the 4,474 cART-eligible women in our cohort, 2,749 (62%) never initiated treatment, 643 
(14%) received ≤8 weeks of cART, 976 (22%) received 9-20 weeks of cART and 103 (2%) 
received 21-36 weeks of cART (Table 2). Of the 2,749 women who never initiated cART, 
81% received zidovudine (with or without single-dose nevirapine) to prevent vertical HIV 
transmission, 13% received only single-dose nevirapine and 6% had no reliable information 
recorded. Among the 1,722 women who initiated cART, the median time from 1st ANC visit 
to cART initiation was 36 days (IQR 24, 64 days).
Women who deliver in a facility may differ from those who deliver at home. To assess 
possible selection bias, women included in the study population were compared with eligible 
women who presented to ANC, but did not deliver in a ZEPRS-supported facility (n=3,921), 
and may have delivered at home. Women with no delivery information were similar to 
women included in the study, with a few exceptions (Web Appendix Table 1). Women 
without delivery information were more likely to have only 1 ANC visit (75% vs. 47%, p-
value <0.01) and less likely to have a cART initiation date recorded (22% vs. 41%, p-value 
<0.01).
Main analyses
In the primary analysis, compared to women who never initiated treatment, there was no 
evidence that receiving cART for ≤8 weeks (RR 1.22, 95% CI: 0.77, 1.91), 9-20 weeks (RR 
1.23, 95% CI: 0.82, 1.83), or 21-36 weeks (RR 0.87, 95% CI: 0.22, 3.46) was associated 
with an increased risk for LBW among infants born at term, after adjustment for multiple 
confounders (Table 2).
Similarly, there was no evidence of an association when birthweight among term infants was 
considered as a continuous outcome. Compared to women who never initiated cART, the 
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mean birthweight for women receiving ≤8 weeks of cART was lower by 2.35 grams (95 % 
CI: -53.69, 49.98), lower by 44.19 grams for women receiving 9-20 weeks of cART (95% 
CI: -89.55, 1.17) and lower by 65.77 grams for women receiving 21-36 weeks of cART 
(95% CI: -194.92, 63.38). The distribution of birthweights between exposure categories, 
stratified by gestational age, did not differ meaningfully (Web Appendix Figure 2). When 
weeks on cART before delivery was considered as a continuous measure, a one-week 
increase in duration on cART before delivery was associated with a decrease in mean 
birthweight of 2.53 grams (95% CI -5.40, 0.35) (Table 3).
Sensitivity analyses and imputation of missing data
Our results were consistent across several sensitivity analyses, although sample size was 
limited in some analyses. When women on cART were compared with non-initiators with 
the same duration of ANC, the RR was 4.20 (95% CI: 0.81, 21.82) for ≤8 weeks of cART, 
1.08 (95%CI: 0.71, 1.64) for 9-20 weeks of cART and 0.95 (95% CI: 0.18, 4.92) for 21-36 
weeks of cART. Similar findings were observed when we stratified by baseline CD4 count, 
when cART duration was assessed at 37 weeks gestation and when women who initiated 
cART with a CD4 >350 were included (Figure 2).
A high proportion of CD4 counts, cART initiation dates and confounder data were missing. 
Among 50,765 HIV-infected pregnant women, 32% (n=16,324) were missing CD4 counts. 
Of the 4,474 women included in the study, 62% (n=2,773) had ≥1 missing confounder. An 
additional 1,002 (18%) women, not included in the primary analysis, were on cART at 
delivery but were missing a cART initiation date. In general, performing multiple 
imputation improved precision but resulted in similar point estimates. When all missing data 
were imputed, point estimates were similar to the primary analysis; receiving cART ≤8 
weeks was associated with RR 1.15 (95% CI: 0.87, 1.54), 9-20 weeks RR 1.35 (95% CI: 
1.07, 1.70) and 21-36 weeks RR 0.96 (95% CI: 0.52, 1.79).
Discussion
Main findings
Among HIV-infected women with CD4 count ≤350 who were treatment-naïve at entry into 
ANC and who delivered at ≥37 weeks, longer duration of cART during pregnancy did not 
result in increased risk of LBW or decreased mean birthweight. These findings did not 
change meaningfully across numerous sensitivity analyses. Modest decreases in birthweight 
were observed with increasing cART duration when cART duration was considered as a 
continuous measure. However, this small decrease must be weighed against the substantial 
benefits of cART in preventing mother-to-child (PMTCT) transmission. Our analysis 
included only term births, and therefore our findings are focused on LBW, a proxy for IUGR 
in this population.
Limitations and Strengths
We note several limitations of this work. First, birthweight measurements were considered 
more reliable than gestational age dating in our data. However, there is some evidence of 
digit-preference in birthweight around 3,000 grams (Web Appendix Figure 2), which may 
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lead to underestimates in the proportion of LBW infants in our cohort. Second, we did not 
have access to information on important confounders, including infant HIV status, markers 
of maternal HIV disease (e.g., viral load, WHO clinical stage), antiretroviral regimens or 
adherence. Second, as with all analyses of routinely collected clinical data, selection bias 
may arise since not all women present for care. However, clinical findings are applicable 
only in clinical settings, so associations observed among those who present for care may be 
generalizable to other populations in care. In addition, our analysis cohort did not include 
pregnant women who miscarried or delivered prior to seeking institutional healthcare, which 
could limit the external validity of our results. Third, if duration of cART is associated with 
preterm birth, restricting to a population of infants born at term may bias analyses aimed at 
generalizing to a population of infants born preterm and at term.(37) In our analysis, we 
limited external validity (e.g. generalizability) in an effort to provide internally valid 
estimates for a population of infants born at term. Fourth, despite limiting our analyses to 
term births, measurement error in gestational age may still be present (Web Appendix 
Figure 1). Finally, reported effect estimates for women on cART for 21-36 weeks and ≤ 8 
weeks were imprecise due to the small numbers of women in these categories.
Strengths of our study included the use of data from an electronic medical record system 
covering 24 public health clinics in Lusaka, the use of a study population with uniform 
eligibility for cART initiation and the consistency of results across multiple sensitivity 
analyses. In addition, our analysis provides some of the first evidence about the relationship 
between duration of cART and the risk of LBW due to fetal growth restriction among HIV-
infected women in SSA.
Interpretation
The aim of this analysis was to determine the association between cART duration during 
pregnancy and LBW among infants born at term. Our findings are consistent with other 
work looking at treatment duration and LBW among term and preterm births. cART 
initiated either early during pregnancy (≤25 or <28 weeks gestation) or late (≥28 or 32 
weeks gestation) was not associated with LBW in studies in South Africa and the US.(6, 38) 
However, since term and preterm births were combined in these studies – without further 
stratification as in this report – it is difficult to distinguish whether late initiators had no 
increased risk of LBW, or were simply less likely to have a PTB (and therefore LBW) by 
virtue of starting treatment later during pregnancy. Birthweight Z-scores adjusted for 
gestational age were considered in a French study and no association with duration of cART 
was found.(39) An analysis from Malawi and Mozambique attempted to stratify by 
gestational age at birth, but was unable to investigate the association between duration of 
cART and LBW among term infants due to the small sample size (n=496).(40) Our study, 
therefore, provides some of the first evidence from SSA on associations between duration of 
cART and LBW due to fetal growth restriction.
PI-based cART has been hypothesized to impact fetal growth by inhibiting progesterone 
production during pregnancy.(41) Among HIV-uninfected women, low progesterone levels 
have been associated with lower birthweights.(42, 43) In animal models, PI-based cART 
regimens have been associated with decreased progesterone levels, which correlated with 
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lower fetal weight.(41) Recent findings from the IMPAACT PROMISE study suggest that 
PI-based cART increases the risk of both LBW and PTB.(44) In Zambia, women initiating 
treatment during pregnancy start NNRTI-based cART.(29-31) PI-based cART is reserved 
for second line therapy, which may be one reason we did not observe an association between 
duration of cART and LBW among infants born at term.
Although the association between cART duration and PTB is of significant interest, we were 
unable to examine this specific research question in the current context. Studying the 
relationship between duration of cART and PTB is difficult because duration of treatment is 
directly related to length of gestation and timing of delivery. Women on cART longer are, 
by definition, closer to term and therefore less likely to have a PTB. In populations at high 
risk for PTB, this could result in longer durations of cART looking protective against PTB. 
Because of these constraints, we restricted our analysis to term births and focused on an 
outcome of LBW due growth restriction. Given our focus on LBW among infants born at 
term, as a proxy for IUGR, our results may be helpful to clinicians caring for patients at low-
risk for PTB. Additional work is needed to understand how duration of cART may affect 
preterm delivery.
Finally, this cannot establish causality and we caution against over interpretation in this 
regard. Prospective randomized studies investigating the effect of timing of cART initiation 
on LBW could help to establish causality. However, such a randomized study would pose 
serious ethical challenges, and might itself leave questions unanswered since women 
included in randomized controlled trials are often a highly selected group, and may not be 
generalizable to a real-world clinical population of HIV-infected pregnant women. Analysis 
of retrospective routinely collected clinical data can only establish causality under critical 
(and empirically unverifiable) assumptions including no uncontrolled confounding and 
treatment variation irrelevance, also known as the consistency assumption.(45) However, 
given the challenges of understanding how timing of treatment may impact LBW, analysis 
of routinely collected clinical data still provides important information about LBW trends 
among women initiating cART during pregnancy.
In our cohort, there was no evidence that longer duration of cART was associated with poor 
fetal growth among term pregnancies. Despite slight decreases in birthweight with 
increasing cART duration, the benefits of cART during pregnancy for PMTCT continue to 
outweigh the risks. Our findings remained consistent across numerous sensitivities analyses, 
providing some level of reassurance about our primary findings. However, the relationship 
between cART use and adverse pregnancy outcomes – particularly those associated with 
PTB – remain complicated and continued work is required to investigate causality. While 
beyond the scope of the current analysis, future research should also investigate whether 
cART use from conception increases the risk of LBW or PTB. An understanding of the 
relationship between cART and adverse pregnancy outcomes is of particular importance, as 
maternal combination regimens become the cornerstone of PMTCT programs globally.
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Figure 1. 
Inclusion criteria for 4,747 term births among HIV-infected pregnant women included in the 
study population. *Duration of cART could not be calculated for 3 women who had no 
delivery date available.
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Figure 2. 
Risk ratios and 95% confidence intervals for the association between duration of cART and 
LBW, among term infants. a Adjusted for: number of ANC visits, age, BMI, CD4 count, 
education, hemoglobin, parity, previous preterm birth and gestational age at birth. b 
Adjusted for: number of ANC visits, age, BMI, education, hemoglobin, parity, previous 
preterm birth and gestational age at birth.
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Table 3
Results for the association between duration of cART before delivery and birthweight.
Exposure Specification Mean Birthweight (g) (SD)
Unadjusted Mean Change in 
Birthweight (95% CI)
Adjusted Mean Change in 
Birthweight a (95% CI)
Weeks on cART before delivery, 
continuous
3040.00 (428.19) -3.23 (-5.20, -1.26) -2.53 (-5.40, 0.35)
Weeks on cART before delivery
 21-36 3059.90 (421.46) 1.89 (-83.85, 87.62) -65.77 (-194.92, 63.38)
 9-20 2995.79 (418.38) -62.22 (-93.79, -30.65) -44.19 (-89.55, 1.17)
 ≤8 3027.44 (439.57) -30.57 (-67.52, 6.37) -2.35 (-54.69, 49.98)
 Never initiated 3058.01 (428.22) 0.00 0.00
aAdjusted for: number of ANC visits, age, BMI, CD4 count, education, hemoglobin, parity, previous preterm birth and gestational age at birth.
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